Key Capital is focused on the further development, and the securing of regulatory approval for its Immunitor partnered suite of 12 developed clinically proven cancer vaccines. Key Biotec, a division of Key Capital will manage all other Immunitor vaccines.
Over the past 20 years, Immunitor has firmly established the science supporting its immunotherapy Vaccines and its patented oral pill delivery advantages by developing and testing over 24 products for the treatment of cancer and many infectious and malignant diseases. In clinical studies and limited public use these products have demonstrated superior safety and efficacy in late-stage cancers, tuberculosis, HIV/AIDS, hepatitis, and many other conditions.
The patented Immunitor oral pill platform technology has the potential to ultimately provide for world-wide equitable access to superior disease treatments, and virus and infection vaccines.